Chronic kidney disease associated cardiomyopathy: recent advances and future perspectives
Authors:
- 5 January 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 33 (2) , 203-211
Abstract
Purpose of review: Cardiomyopathy in chronic kidney disease (CKD) is a complex condition with multiple triggers and poor prognosis. This review provides an overview of recent advances in CKD-associated cardiomyopathy, with a focus on pathophysiology, newly discovered biomarkers and potential therapeutic targets. Recent findings: CKD is associated with a specific pattern of myocardial hypertrophy and fibrosis, resulting in diastolic and systolic dysfunction, and often triggered by nonatherosclerotic processes. Novel biomarkers, including amino-terminal type III procollagen peptide (PIIINP), carboxy-terminal type I procollagen peptide (PICP), FGF23, marinobufagenin, and several miRNAs, show promise for early detection and risk stratification. Treatment options for CKD-associated cardiomyopathy are limited. Sodium glucose cotransporter-2 inhibitors have been shown to reduce left ventricle hypertrophy and improve ejection fraction in individuals with diabetes and mild CKD, and are currently under investigation for more advanced stages of CKD. In hemodialysis patients calcimimetic etelcalcetide resulted in a significant reduction in left ventricular mass. Summary: CKD-associated cardiomyopathy is a common and severe complication in CKD. The identification of novel biomarkers may lead to future therapeutic targets. Randomized clinical trials in individuals with more advanced CKD would be well posed to expand treatment options for this debilitating condition.Keywords
This publication has 97 references indexed in Scilit:
- European cardiovascular magnetic resonance (EuroCMR) registry – multi national results from 57 centers in 15 countriesJournal of Cardiovascular Magnetic Resonance, 2013
- Expect the UnexpectedClinical Journal of the American Society of Nephrology, 2012
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Sudden Cardiac Death in End-Stage Renal Disease PatientsHypertension, 2010
- Left Ventricular Mass in Chronic Kidney Disease and ESRDClinical Journal of the American Society of Nephrology, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- NON‐CORONARY HEART DISEASE IN DIALYSIS PATIENTS: Hypertrophy and Fibrosis in the Cardiomyopathy of Uremia—Beyond Coronary Heart DiseaseSeminars in Dialysis, 2008
- Morphology of the heart and arteries in renal failureKidney International, 2003
- Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysisKidney International, 2002
- Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosisThe American Journal of Cardiology, 1995